Skip to main content
logo
AbCellera Biologics Inc. (ABCL)
NASDAQ: ABCL · Real-Time Price · USD
11.36
+0.08 (0.71%)
At close: Sep 2, 2026, 4:00 PM EDT
11.29
-0.07 (-0.62%)
Pre-market: Sep 3, 2026, 4:00 AM EDT

AbCellera Biologics Cash Flow Statement

Millions USD. Fiscal year is Jan - Dec.

Operating Activities

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Jun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Net Income
-164.66-146.41-162.86-146.4158.52153.46
Depreciation & Amortization
32.5928.826530.8924.717.25
Asset Writedown & Restructuring Costs
--32-8.4-
Stock-Based Compensation
51.155.7967.5864.1849.4830.65
Other Operating Activities
8.151.2-84.44-5.786.431.55
Change in Accounts Receivable
-17.73-55.62-75.12-45.93106.4622.48
Change in Accounts Payable
-5.813.4610.64-15.1-2.09-3.24
Change in Unearned Revenue
26.16-5.8326.0425.5515.4539.34
Change in Income Taxes
-30.28-29.846.6530.46-88.61-13.53
Change in Other Net Operating Assets
5.5417.155.9518.25-1.38-3.38
Operating Cash Flow
-94.94-131.3-108.56-43.88277.36244.58
Operating Cash Flow Growth
----13.40%977.94%

Investing Activities

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Jun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Capital Expenditures
-24.73-42.77-78.4-76.95-70.66-58.45
Cash Acquisitions
------11.46
Sale (Purchase) of Intangibles
-----2-
Investment in Securities
67.575.91164.1-169.47-296.4-294.96
Other Investing Activities
55.1254.6135.7125.3116.4332.62
Investing Cash Flow
97.8987.75121.41-221.11-352.63-332.25

Financing Activities

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Jun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Long-Term Debt Issued
-29.7313.511.592.765.49
Total Debt Issued
29.7329.7313.511.592.765.49
Net Debt Issued (Repaid)
29.7329.7313.511.592.765.49
Other Financing Activities
-4.66-15.65-0.73-1.23-4.38-9.37
Financing Cash Flow
25.0714.0812.7710.36-1.63-3.89

Net Cash Flow

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Jun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Foreign Exchange Rate Adjustments
-0.721.1-2.620.59-9.6-1.43
Net Cash Flow
27.3-28.3723.01-254.04-86.49-92.97

Free Cash Flow

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Jun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Free Cash Flow
-119.67-174.07-186.95-120.82206.7186.13
Free Cash Flow Growth
----11.05%1329.91%
Free Cash Flow Margin
-180.85%-231.69%-648.40%-317.75%42.58%49.61%
Free Cash Flow Per Share
-0.40-0.58-0.64-0.420.660.58
Levered Free Cash Flow
-46.43-176-177.77-102.4205.62143.8
Unlevered Free Cash Flow
-46.43-176-177.77-102.4205.62143.8

Additional Metrics

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Jun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Change in Working Capital
-22.12-70.69-25.8413.2329.8341.67
SEC Filings: 10-K · 10-Q